智翔金泰：预计2025年全年净亏损48063.73万元—58744.56万元

Core Viewpoint - The company expects a significant net loss for the year 2025, despite a substantial increase in revenue driven by the sales of its first commercial product and licensing income from a new agreement [1] Financial Performance - The projected net profit attributable to shareholders for 2025 is estimated to be between -480.64 million and -587.45 million yuan [1] - The projected net profit attributable to shareholders after deducting non-recurring gains and losses is estimated to be between -523.63 million and -630.44 million yuan [1] - The company reported a substantial increase in operating revenue compared to the same period last year, primarily due to steady sales growth of its commercial product, Glinix® [1] Research and Development - The company maintains a high level of R&D investment as multiple products enter clinical research stages and core products advance to critical clinical trial phases [1] - The company has implemented an equity incentive plan for its core team, which will not incur share-based payment expenses in 2025, leading to a reduction in corresponding costs [1] Overall Outlook - Despite the expected losses for 2025, the company anticipates a significant narrowing of the loss compared to the previous year [1]